Clinical Trial Update: Miglustat / OGT 918 in the Treatment of Cystic Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating miglustat (OGT-918) for cystic fibrosis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Miglustat (OGT-918) (miglustat)

Snippet

Sponsor: Actelion | Conditions: Cystic Fibrosis | Phase 2 | Status: TERMINATED